Corpus overview


MeSH Disease

Human Phenotype

Diarrhea (127)

Fever (80)

Cough (77)

Fatigue (38)

Pneumonia (32)


    displaying 1 - 10 records in total 127
    records per page

    Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia HP pneumonia MESHD: 2 an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-3 COVID-19.

    Authors: Manuel Rubio-Rivas; Xavier Corbella; Jose Maria Mora-Lujan; Jose Loureiro Amigo; Almudena Lopez Sampalo; Carmen Yera Bergua; Pedro Jesus Esteve Atienzar; Luis Felipe Diez Garcia; Ruth Gonzalez Ferrer; Susana Plaza Canteli; Antia Perez Pineiro; Begona Cortes Rodriguez; Leyre Jorquer Vidal; Ignacio Perez Catalan; Marta Leon Tellez; Jose Angel Martin Oterino; Maria Candelaria Martin Gonzalez; Jose Luis Serrano Carrillo de Albornoz; Eva Garcia Sardon; Jose Nicolas Alcala Pedrajas; Anabel Martin Urda Diez Canseco; Maria Jose Esteban Giner; Pablo Telleria Gomez; Ricardo Gomez Huelgas; Jose Manuel Ramos Rincon; Nina la Cour Freiesleben; Henriette Svarre Nielsen

    doi:10.1101/2020.09.14.20193995 Date: 2020-09-15 Source: medRxiv

    (1) Background: This study aims to identify different clinical phenotypes in COVID-19 88 pneumonia HP pneumonia MESHD using cluster analysis and to assess the prognostic impact among identified clusters in 89 such patients. (2) Methods: Cluster analysis including 11 phenotypic variables was performed in a 90 large cohort of 12,066 COVID-19 patients, collected and followed-up from March 1, to July 31, 2020, 91 from the nationwide Spanish SEMI-COVID-19 Registry. (3) Results: Of the total of 12,066 patients 92 included in the study, most were males TRANS (7,052, 58.5%) and Caucasian (10,635, 89.5%), with a mean 93 age TRANS at diagnosis of 67 years (SD 16). The main pre-admission comorbidities were arterial 94 hypertension HP hypertension MESHD (6,030, 50%), hyperlipidemia HP hyperlipidemia MESHD (4,741, 39.4%) and diabetes mellitus HP diabetes mellitus MESHD (2,309, 19.2%). The 95 average number of days from COVID-19 symptom onset TRANS to hospital admission was 6.7 days (SD 7). 96 The triad of fever HP fever MESHD, cough HP cough MESHD, and dyspnea HP dyspnea MESHD was present almost uniformly in all 4 clinical phenotypes 97 identified by clustering. Cluster C1 (8,737 patients, 72.4%) was the largest, and comprised patients 98 with the triad alone. Cluster C2 (1,196 patients, 9.9%) also presented with ageusia and anosmia MESHD anosmia HP; 99 cluster C3 (880 patients, 7.3%) also had arthromyalgia, headache HP headache MESHD, and sore throat; and cluster C4 100 (1,253 patients, 10.4%) also manifested with diarrhea HP diarrhea MESHD, vomiting HP vomiting MESHD, and abdominal pain HP abdominal pain MESHD. Compared to 101 each other, cluster C1 presented the highest in-hospital mortality (24.1% vs. 4.3% vs. 14.7% vs. 102 18.6%; p<0.001). The multivariate study identified phenotypic clusters as an independent factor for 103 in-hospital death. (4) Conclusion: The present study identified 4 phenotypic clusters in patients with 104 COVID-19 pneumonia HP pneumonia MESHD, which predicted the in-hospital prognosis of clinical outcomes.

    Clinical characteristics of pediatric cases of SARS-CoV-2 infection MESHD in Hunan, China: A retrospective, multi-center case series

    Authors: Lei Wu; Xiao-Fo Zhang; Jia Li; Song-Qing Wei; Yong Yang; Xiu-Ying Yi; Xin-Ping Jiang; Hai-Ying Han; Zhe-Feng Zhong; Xiao-Ying Cao; Feng-Jun L; Ge Zhou; Xiao-Hui Gong; Wen-Ting Zha; He-Bin Xie; Tuan-Mei Wang; Man-Zhi Wang

    doi:10.21203/ Date: 2020-09-15 Source: ResearchSquare

    Objective To investigate the epidemiological characteristics, clinical features, treatment and short-term prognosis of SARS-CoV-2 infection MESHD in children TRANS.Methods A retrospective analysis was conducted in children TRANS with SARS-CoV-2 admitted to twelve hospitals in eight cities in Hunan province, China, from January 26, 2020 to June 30, 2020.Results A total of 48 children were enrolled in this study. 11 cases (23%) were asymptomatic TRANS, 15 cases (31%) were mild, 20 cases (42%) were moderate, and 2 cases (4%) were severe. No children TRANS were critical requiring intensive care. The most common symptom was fever HP fever MESHD (42%), cough HP (40%), fatigue MESHD (17%) and diarrhea HP diarrhea MESHD (10%). The total peripheral blood SERO leukocytes count decreased in two case (4%), Lymphocytopenia MESHD was present in 5 cases (10%). There were abnormal chest CT changes in 22 children (46%), including 15 (68%) with patchy ground glass opacity. In addition to supportive treatment, 41 children TRANS (85%) received antiviral therapy, 11 patients and (23%) were treated with antibiotics, 2 children TRANS (4%) were treated with methylprednisolone and IVIG. There was no death occurred.Conclusions Most children TRANS with SARS CoV-2 infection MESHD in Hunan province were asymptomatic TRANS, mild or moderate. Severe cases are rare. Close family contact was the main route of infection MESHD. The younger the age TRANS, the less obvious symptoms for children TRANS might be. Epidemiological history, nucleic acid test and chest imaging were important tools for the diagnosis in children TRANS.

    New onset of Myasthenia Gravis MESHD in a patient with COVID-19: A novel case report and literature review

    Authors: Shitiz Sriwastava; Medha Tandon; Saurabh Kataria; Maha Daimee; Shumaila Sultan

    doi:10.21203/ Date: 2020-09-14 Source: ResearchSquare

    The novel coronavirus outbreak of SARS-CoV-2 first began in Wuhan, China in December, 2019. The most striking manifestation is atypical pneumonia HP pneumonia MESHD and respiratory complications MESHD, however various neurological manifestations are now well recognized. Currently, there have been a very few case reports in regards to COVID-19 in patients with known history of myasthenia gravis MESHD. Myasthenia gravis MESHD ( MG MESHD) causes muscle weakness HP muscle weakness MESHD, especially respiratory muscles in high-risk COVID-19 patients that can lead to severe respiratory compromise. There are few reported cases of severe myasthenia crisis MESHD following COVID-19, likely due to the involvement of the respiratory apparatus and from use of immunosuppressive medication. We report a first case MG MESHD developing secondary to COVID-19 infection MESHD in a 65-year-old woman. Two weeks prior to hospitalization, the patient suffered from cough HP, fever HP fever MESHD, diarrhea HP diarrhea MESHD and was found to be positive for COVID-19 via nasopharyngeal RT-PCR swab test. The electrodiagnostic test showed decremental response over more than 10% on repetitive nerve stimulation test of orbicularis oculi. She tested positive for antibodies SERO against Acetylcholine receptor (AchR).COVID-19 is known to cause release of inflammatory cytokines leading to immune-mediated damage. MG MESHD is an immune-mediated disorder caused due to molecular mimicry and autoantibodies against the neuromuscular junction. 

    Clinical Characteristics, Risk Factors and Predictive Value of COVID-19 Pneumonia HP: A Retrospective Study of 173 Patients in Wuhan, China

    Authors: Yang Zhang; Jun Xue; Mi Yan; Jing Chen; Hai Liu; Shao-Bo Wang; Jian-Xing Luo; Fang Yang; Jian-Yuan Tang; Xiao-Yu Hu

    doi:10.21203/ Date: 2020-09-11 Source: ResearchSquare

    Background: COVID-19 is a globally emerging infectious disease MESHD. As the global epidemic continues to spread, the risk of COVID-19 transmission TRANS and diffusion in the world will also remain. Currently, several studies describing its clinical characteristics have focused on the initial outbreak, but rarely to the later stage. Here we described clinical characteristics, risk factors for disease severity and in-hospital outcome in patients with COVID-19 pneumonia HP pneumonia MESHD from Wuhan. Methods: Patients with COVID-19 pneumonia HP pneumonia MESHD admitted to Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from February 13 to March 8, 2020, were retrospectively enrolled. Multivariable logistic regression analysis was used to identify risk factors for disease severity and in-hospital outcome and establish predictive models. Receiver operating characteristic (ROC) curve was used to assess the predictive value of above models.Results: 106 (61.3%) of the patients were female TRANS. The mean age TRANS of study populations was 62.0 years, of whom 73 (42.2%) had underlying comorbidities mainly including hypertension HP hypertension MESHD (24.9%). The most common symptoms on admission were fever HP fever MESHD (67.6%) and cough HP (60.1%), digestive symptoms (22.0%) was also very common. Older age TRANS (OR: 3.420; 95%Cl: 1.415-8.266; P=0.006), diarrhea HP diarrhea MESHD (OR: 0.143; 95%Cl: 0.033-0.611; P=0.009) and lymphopenia HP lymphopenia MESHD (OR: 4.769; 95%Cl: 2.019-11.266; P=0.000) were associated with severe illness on admission; the area under the ROC curve (AUC) of predictive model were 0.860 (95%CI: 0.802-0.918; P=0.000). Older age TRANS (OR: 0.309; 95%Cl: 0.142-0.674; P=0.003), leucopenia (OR: 0.165; 95%Cl: 0.034-0.793; P=0.025), increased lactic dehydrogenase (OR: 0.257; 95%Cl: 0.100-0.659; P=0.005) and interleukins-6 levels (OR: 0.294; 95%Cl: 0.099-0.872; P=0.027) were associated with poor in-hospital outcome; AUC of predictive model were 0.752 (95%CI: 0.681-0.824; P=0.000).Conclusion: Older patients with diarrhea HP diarrhea MESHD and lymphopenia HP lymphopenia MESHD need early identification and timely intervention to prevent the progression to severe COVID-19 pneumonia HP pneumonia MESHD. However, older patients with leucopenia, increased lactic dehydrogenase and interleukins-6 levels are at a high risk for poor in-hospital outcome.Trial registration: ChiCTR2000029549

    SARS-CoV-2-specific IgA and limited inflammatory cytokines are present in the stool of select patients with acute COVID-19

    Authors: Graham J Britton; Alice Chen-Liaw; Francesca Cossarini; Alexandra E Livanos; Matthew P Spindler; Tamar Plitt; Joseph Eggers; Ilaria Mogno; Ana Gonzalez-Reiche; Sophia Siu; Michael Tankelevich; Lauren Grinspan; Rebekah E Dixon; Divya Jha; Gustavo Martinez-Delgado; Fatima Amanat; Daisy A Hoagland; Benjamin tenOever; Marla C Dubinsky; Miriam Merad; Harm van Bakel; Florian Krammer; Gerold Bongers; Saurabh Mehandru; Jeremiah J Faith

    doi:10.1101/2020.09.03.20183947 Date: 2020-09-05 Source: medRxiv

    Background and aims: Immune dysregulation HP dysregulation MESHD caused by SARS-CoV-2 infection MESHD is thought to play a pathogenic role in COVID-19. SARS-CoV-2 can infect a variety of host cells, including intestinal epithelial cells. We sought to characterize the role of the gastrointestinal immune system in the pathogenesis of the inflammatory response associated with COVID-19. Methods: We measured cytokines, inflammatory markers, viral RNA, microbiome composition and antibody SERO responses in stool and serum samples SERO from a prospectively enrolled cohort of 44 hospitalized COVID-19 patients. Results: SARS-CoV-2 RNA was detected in stool of 41% of patients and was found more frequently in patients with diarrhea HP diarrhea MESHD than those without (16[44%] vs 5[19%], p=0.06). Patients who survived had lower median viral genome copies than those who did not (p=0.021). Compared to uninfected controls, COVID-19 patients had higher median fecal levels of IL-8 (166.5 vs 286.5 pg/mg; p=0.05) and lower levels of fecal IL-10 (678 vs 194 pg/mg; p<0.001) compared to uninfected controls. Stool IL-23 was higher in patients with more severe COVID-19 disease (223.8 vs 86.6 pg/mg; p=0.03) and we find evidence of intestinal virus-specific IgA responses, which was associated with more severe disease. Fecal cytokines and calprotectin levels were not correlated with gastrointestinal symptoms MESHD or with the level of virus detected. Conclusions: Although SARS-CoV-2 RNA was detectable in the stools of COVID-19 patients and select individuals had evidence for a specific mucosal IgA response, intestinal inflammation MESHD was limited, even in patients presenting with gastrointestinal symptoms MESHD.

    Identifying COVID-19 cases in primary TRANS care settings

    Authors: Yinan Mao; Yi-Roe Tan; Tun-Linn Thein; Louis Chai; Alex Cook; Borame Dickens; Yii-Jen Lew; Fong Seng Lim; Jue Tao Lim; Yinxiaohe Sun; Meena Sundaram; Alexius Soh; Glorijoy Tan; Franco Wong; Barnaby Young; Kangwei Zeng; Mark Chen; Desmond Ong; Zhong Ni; Baoyu Chen; Chunping Du; Hongchen He; Yun Qu; Quan Wei; Chengqi He; Jan D. Reinhardt

    doi:10.1101/2020.08.26.20182204 Date: 2020-09-01 Source: medRxiv

    Case identification is an ongoing issue for the COVID-19 epidemic, in particular for outpatient care where physicians must decide which patients to prioritise for further testing. This paper reports tools to classify patients based on symptom profiles based on 236 SARS-CoV-2 positive cases and 564 controls, accounting for the time course of illness at point of assessment. Clinical differentiators of cases and controls were used to derive model-based risk scores. Significant symptoms included abdominal pain HP abdominal pain MESHD, cough HP, diarrhea HP diarrhea MESHD, fever HP fever MESHD, headache HP headache MESHD, muscle ache MESHD, runny nose, sore throat, temperature between 37.5{degrees}C and 37.9{degrees}C, and temperature above 38{degrees}C, but their importance varied by day of illness at assessment. With a high percentile threshold for specificity at 0.95, the baseline model had reasonable sensitivity SERO at 0.67. To further evaluate accuracy of model predictions, we firstly used leave-one-out cross-validation, which confirmed high classification accuracy with an area under the receiver operating characteristic curve of 0.92. For the baseline model, sensitivity SERO decreased to 0.56. Secondly, in a separate ongoing prospective study of 237 COVID-19 and 346 primary care patients presenting with symptoms of acute respiratory infection MESHD, the baseline model had a sensitivity SERO of 0.57 and specificity of 0.89, and in retrospective notes review of 100 COVID-19 cases diagnosed in primary care, sensitivity SERO was 0.56. A web-app based tool has been developed for easy implementation as an adjunct to laboratory testing to differentiate COVID-19 positive cases among patients presenting in outpatient settings.

    Clinical Characteristics of Mild/moderate COVID-19 Patients with a Prolonged Negative Conversion Time of SARS-CoV-2 Nucleic Acid Detection

    Authors: Ya Yang; Xiaogang Hu; Lirong Xiong; Peishu Fu; Wei Feng; Wei Li; Liwen Zhang; Fengjun Sun

    doi:10.21203/ Date: 2020-08-29 Source: ResearchSquare

    Background:  The impact of COVID-19 has been devastating on a global scale. Our study aimed to identify factors in predicting prolonged negative conversion time (NCT) of SARS-CoV-2 RNA in mild/moderate COVID-19 patients. Methods: The clinical features and treatment outcomes were retrospectively analyzed from 32 hospitalized mild/moderate COVID-19 patients. Then univariate and multivariate analysis were used to predict in the factors of prolonged NCT of SARS-CoV-2 RNA.Results: The general clinical symptoms were cough HP (78.1%), fever HP fever MESHD (75%), diarrhea HP diarrhea MESHD (68.8%), expectoration (56.3%), and nausea HP nausea MESHD (37.5%). More than 40% of the patients had decreased erythrocyte, hemoglobin and leucocyte and 93.8% patients were detected in abnormalities of chest CT. The median NCT of SARS-CoV-2 RNA was 19.5 days (IQR: 14.25–25). Univariate analysis found fever HP fever MESHD, nausea HP nausea MESHD, diarrhea HP diarrhea MESHD and abnormalities in chest CTs were positively associated with prolonged NCT of viral RNA (P<0.05). The multivariate Cox proportional hazard model revealed that fever HP fever MESHD [Exp (B), 0.284; 95% CI, 0.114‑0.707; P<0.05] and nausea HP nausea MESHD [Exp (B), 0.257; 95%CI, 0.096‑0.689; P<0.05] were two significant independent factors. Conclusions: Fever HP Fever MESHD, nausea HP nausea MESHD, diarrhea HP diarrhea MESHD and abnormalities in chest CT are potential factors for predicting prolonged NCT of viral RNA. Moreover, Fever HP Fever MESHD and nausea HP nausea MESHD were two significant independent factors in prolonged NCT of viral RNA in mild/moderate COVID-19 patients.

    Prevalence SERO and correlation of symptoms and comorbidities in COVID-19 patients: A systematic review and meta-analysis

    Authors: Mohammad Meshbahur Rahman; Badhan Bhattacharjee; Zaki Farhana; Mohammad Hamiduzzaman; Muhammad Abdul Bake Chowdhury; Mohammad Sorowar Hossain; Mahbubul H Siddiqee; Md. Ziaul Islam; Enayetur Raheem; Md. Jamal Uddin

    doi:10.1101/2020.08.19.20177980 Date: 2020-08-22 Source: medRxiv

    Background: The COVID-19 affected millions of people, and the patients present a constellation of symptoms and comorbidities. We aimed to chronicle the prevalence SERO and correlations of symptoms and comorbidities, and associated covariates among the patients. Methods: We performed a systematic review and meta-analysis [PROSPERO registration: CRD42020182677]. Databases [PubMed, SCOPUS, EMBASE, WHO, Semantic Scholar, and COVID-19 Primer] were searched for clinical studies published in English from January 1 to April 20, 2020. The pooled prevalence SERO of symptoms and comorbidities were identified using the random effect model, and sub-groups analysis of patients age TRANS and locations were investigated. A multivariable factor analysis was also performed to show the correlation among symptoms, comorbidities and age TRANS of the COVID-19 patients. Findings: Twenty-nine articles [China (24); Outside of China (5)], with 4,884 COVID-19 patients were included in this systematic review. The meta-analysis investigated 33 symptoms, where fever HP fever MESHD [84%], cough HP cough MESHD/dry cough HP [61%], and fatigue HP fatigue MESHD/weakness [42%] were found frequent. Out of 43 comorbidities investigated, acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD) [61%] was a common condition, followed by hypertension HP hypertension MESHD [23%] and diabetes MESHD [12%]. According to the patients age TRANS, the prevalence SERO of symptoms like fatigue HP fatigue MESHD/weakness, dyspnea HP dyspnea MESHD/shortness of breath, and anorexia HP anorexia MESHD were highly prevalent in older adults TRANS [[≥]50 years] than younger adults TRANS [<50 years]. Diabetes MESHD, hypertension HP hypertension MESHD, coronary heart disease MESHD, and COPD MESHD/ lung disease MESHD were more prevalent comorbidities in older adults TRANS than younger adults TRANS. The patients from outside of China had significantly higher prevalence SERO [p<0.005] of diarrhea HP diarrhea MESHD, fatigue HP fatigue MESHD, nausea HP nausea MESHD, sore throat, and dyspnea HP dyspnea MESHD, and the prevalent comorbidities in that region were diabetes MESHD, hypertension HP hypertension MESHD, coronary heart disease MESHD, and ARDS MESHD. The multivariable factor analysis showed positive association between a group of symptoms and comorbidities, and with the patients age TRANS. Interpretation: Epitomizing the correlation of symptoms of COVID-19 with comorbidities and patients age TRANS would help clinicians effectively manage the patients.

    A Young Adult TRANS with COVID-19 and Multisystem Inflammatory Syndrome MESHD in Children TRANS (MIS-C)-like Illness: A Case Report

    Authors: Aaron D. Kofman; Emma K. Sizemore; Joshua F. Detelich; Benjamin Albrecht; Anne L. Piantadosi

    doi:10.21203/ Date: 2020-08-18 Source: ResearchSquare

    Background: A healthy 25-year-old woman developed COVID-19 disease with clinical characteristics resembling Multisystem Inflammatory Syndrome in Children TRANS (MIS-C), a rare form of COVID-19 described primarily in children TRANS under 21 years of age TRANS.Case Presentation: The patient presented with one week of weakness MESHD, dyspnea HP dyspnea MESHD, and low-grade fevers HP, followed by mild cough HP, sore throat, vomiting HP vomiting MESHD, diarrhea HP diarrhea MESHD, and lymph node swelling MESHD. She was otherwise healthy, with no prior medical history. Her hospital course was notable for profound acute kidney injury HP acute kidney injury MESHD, leukocytosis HP leukocytosis MESHD, hypotension HP hypotension MESHD, and cardiac dysfunction MESHD requiring ICU admission and vasopressor support. MIS-C-like illness secondary to COVID-19 was suspected due to physical exam findings of conjunctivitis HP conjunctivitis MESHD, mucositis MESHD, and shock HP. She improved following IVIG, aspirin, and supportive care, and was discharged on hospital day 5.Conclusion: MIS-C-like illness should be considered in adults TRANS presenting with atypical clinical findings and concern for COVID-19. Further research is needed to support the role of IVIG and aspirin in this patient population.

    Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial

    Authors: Maria Isabel F Lopes; Leticia P Bonjorno; Marcela C Giannini; Natalia B Amaral; Maira N Benatti; Uebe C Rezek; Laerte L Emrich-Filho; Betania AA Sousa; Sergio CL Almeida; Rodrigo Luppino-Assad; Flavio P Veras; Ayda Schneider; Tamara S Rodrigues; Luiz OS Leiria; Larissa D Cunha; Jose C Alves-Filho; Thiago M Cunha; Eurico Arruda Neto; Carlos H Miranda; Antonio Pazin-Filho; Maria A Martins; Marcos C Borges; Benedito AL Fonseca; Valdes R Bollela; Cristina M Del-Ben; Fernando Q Cunha Sr.; Dario S Zamboni; Rodrigo C Santana; Fernando C Vilar; Paulo Louzada-Junior; Rene D R Oliveira

    doi:10.1101/2020.08.06.20169573 Date: 2020-08-11 Source: medRxiv

    Introduction. Neutrophilia HP and high levels of proinflammatory cytokines and other mediators of inflammation MESHD are common finds in patients with severe acute respiratory syndrome MESHD due to COVID-19. By its action on leukocytes, we propose colchicine as an intervention worthy of being tested. Objective. To evaluate whether the addition of colchicine to standard treatment for COVID-19 results in better outcomes. Methods. We present the interim analysis of a single-center randomized, double-blinded, placebo controlled clinical trial of colchicine for the treatment of moderate to severe COVID-19, with 38 patients allocated 1:1 from April 11 to July 06, 2020. Colchicine regimen was 0.5 mg thrice daily for 5 days, then 0.5 mg twice daily for 5 days. The first dose was 1.0 mg whether body weight was [≥] 80 kg. Endpoints. The primary endpoints were the need for supplemental oxygen; time of hospitalization; need for admission and length of stay in intensive care units; and death rate and causes of mortality. As secondary endpoints, we assessed: serum SERO C-reactive protein, serum SERO Lactate dehydrogenase and relation neutrophil to lymphocyte of peripheral blood SERO samples from day zero to day 7; the number, type, and severity of adverse events; frequency of interruption of the study protocol due to adverse events; and frequency of QT interval above 450 ms. Results. Thirty-five patients (18 for Placebo and 17 for Colchicine) completed the study. Both groups were comparable in terms of demographic, clinical and laboratory data at baseline. Median (and interquartile range) time of need for supplemental oxygen was 3.0 (1.5-6.5) days for the Colchicine group and 7.0 (3.0-8.5) days for Placebo group (p = 0.02). Median (IQR) time of hospitalization was 6.0 (4.0-8.5) days for the Colchicine group and 8.5 (5.5-11.0) days for Placebo group (p = 0.03). At day 2, 53% vs 83% of patients maintained the need for supplemental oxygen, while at day 7 the values were 6% vs 39%, in the Colchicine and Placebo groups, respectively (log rank; p = 0.01). Hospitalization was maintained for 53% vs 78% of patients at day 5 and 6% vs 17% at day 10, for the Colchicine and Placebo groups, respectively (log rank; p = 0.01). One patient per group needed admission to ICU. No recruited patient died. At day 4, patients of Colchicine group presented significant reduction of serum SERO C-reactive protein compared to baseline (p < 0.001). The majority of adverse events were mild and did not lead to patient withdrawal. Diarrhea HP Diarrhea MESHD was more frequent in the Colchicine group (p = 0.17). Cardiac adverse events were absent. Discussion. The use of colchicine reduced the length of supplemental oxygen therapy and the length of hospitalization. Clinical improvement was in parallel with a reduction on serum SERO levels of C-reactive protein. The drug was safe and well tolerated. Colchicine may be considered a beneficial and not expensive option for COVID-19 treatment. Clinical trials with larger numbers of patients should be conducted to further evaluate the efficacy and safety of colchicine as an adjunctive therapy for hospitalized patients with moderate to severe COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.